1988
THE FREQUENCY OF EPSTEIN-BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN
Ho M, Jaffe R, Miller G, Breinig M, Dummer J, Makowka L, Atchison R, Karrer F, Nalesnik M, Starzl T. THE FREQUENCY OF EPSTEIN-BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN. Transplantation 1988, 45: 719-726. PMID: 2833828, PMCID: PMC2993427, DOI: 10.1097/00007890-198804000-00011.Peer-Reviewed Original ResearchConceptsLymphoproliferative syndromePrimary infectionEBV infectionTransplant recipientsEpstein-Barr virus infectionMonoclonal B-cell lymphomaPediatric liver recipientsPrimary EBV infectionPediatric transplant recipientsEpstein-Barr virusEBV nuclear antigenB-cell lymphomaLiver recipientsPediatric EBVCyclosporine monitoringEBV DNAClinical typesPediatric casesSecond syndromeVirus infectionCell lymphomaAdditional casesGreater riskInfectionNuclear antigen
1982
Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: Implications for the relationship between African and American Burkitt's lymphoma
Freeman C, Magrath I, Benjamin D, Makuch R, Douglass E, Santaella M. Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: Implications for the relationship between African and American Burkitt's lymphoma. Clinical Immunology 1982, 25: 103-113. PMID: 7151335, DOI: 10.1016/0090-1229(82)90169-6.Peer-Reviewed Original ResearchConceptsEBV nuclear antigenEpstein-Barr virus receptorUndifferentiated lymphomaComplement receptorsExpression of complementEBNA-positive cell linesCell linesVirus receptorAmerican Burkitt's lymphomaCell typesEBV receptorBurkitt's typeReceptor expressionBurkitt's lymphomaNeoplastic counterpartsLymphomaHigh levelsIndividual tumorsVirus producersDegree of expressionNuclear antigenLow levelsReceptorsTumorsEBV
1979
Experimental Carcinogenicity by the Virus In Vivo
Miller G. Experimental Carcinogenicity by the Virus In Vivo. 1979, 351-372. DOI: 10.1007/978-3-642-67236-1_16.Peer-Reviewed Original ResearchEpstein-Barr virusEBV nuclear antigenBurkitt's lymphomaEBV DNA copiesHuman EBV infectionEBV infectionLymphoid folliclesLymphoproliferative syndromeMalignant diseaseGerminal centersLymphoid neoplasmsNew World primatesNuclear antigenSpectrum of responsesOwl monkeysLymphomaInfectionExperimental carcinogenicityVirusDNA copiesNeoplasmsSyndromeTumorsAntigenDisease
1974
OROPHARYNGEAL EXCRETION OF EPSTEIN-BARR VIRUS BY PATIENTS TREATED WITH IMMUNOSUPPRESSIVE DRUGS
Siegel N, Strauch B, Andrews L, Miller G, Cook C. OROPHARYNGEAL EXCRETION OF EPSTEIN-BARR VIRUS BY PATIENTS TREATED WITH IMMUNOSUPPRESSIVE DRUGS. Pediatric Research 1974, 8: 428-428. DOI: 10.1203/00006450-197404000-00531.Peer-Reviewed Original ResearchEpstein-Barr virusRenal homograftsImmunosuppressive agentsImmunosuppressive drugsHuman umbilical cord leukocytesRenal transplant recipientsLatent EBV infectionEBV capsid antigenEBV nuclear antigenUmbilical cord leukocytesRate of excretionOropharyngeal excretionEBV infectionImmunosuppressive therapySeropositive patientsTransplant recipientsCapsid antigenThroat washingsVirus 8Chronic uremiaThroat samplesHealthy controlsPatientsExcretion rateExcretion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply